title: Prescriptions of dialysate potassium concentration during short daily or long nocturnal (high dose) hemodialysis.
abstract: The prescription of dialysate potassium concentration during short daily and long nocturnal (high dose) hemodialysis (HD) is challenging due to limited clinical experience with such modalities. The aim here is to propose a quantitative approach for prescribing dialysate potassium concentrations during high-dose HD. Potassium kinetic parameters based on a pseudo one-compartment model from 547 patients participating in the HEMO Study were used for prediction purposes in this study. Patients were categorized based on the prescribed dialysate potassium concentration during thrice weekly HD as 1K (mean of 1.02 mEq/L, N = 60), 2K (2.01 mEq/L, N = 437), or 3K (3.01 mEq/L, N = 50). Dialysate potassium concentrations were then predicted for each patient during short daily and long nocturnal HD based on a pseudo one-compartment model to maintain the identical weekly dialytic potassium removal and predialysis serum potassium concentration as during thrice weekly HD. Predicted prescribed dialysate potassium concentrations for short daily HD were 0.18-0.45 mEq/L higher than during thrice weekly HD but were approximately 4 (3.72-4.26) mEq/L for all patients during long nocturnal HD. The intradialytic decrease in serum potassium concentration was predicted to be reduced by more than one-half during short daily HD and by approximately three-quarters during long nocturnal HD of that during thrice weekly HD. Prescribed dialysate potassium concentration during high-dose HD modalities can be quantitatively predicted using a pseudo one-compartment kinetic model. High-dose HD modalities may improve clinical outcomes by reducing intradialytic decreases in serum potassium.
authors.affiliation: Medical Products (Renal), Baxter Healthcare Corporation, Deerfield, Illinois, USA.
authors.forename: John K
authors.initials: JK
authors.lastname: Leypoldt
authors.affiliation: Medical Products (Renal), Baxter Healthcare Corporation, Deerfield, Illinois, USA.
authors.forename: Baris U
authors.initials: BU
authors.lastname: Agar
authors.affiliation: Medical Products (Renal), Baxter Healthcare Corporation, Deerfield, Illinois, USA.
authors.forename: Angelito A
authors.initials: AA
authors.lastname: Bernardo
authors.affiliation: Medical Products (Renal), Baxter Healthcare Corporation, Deerfield, Illinois, USA.
authors.forename: Bruce F
authors.initials: BF
authors.lastname: Culleton
mesh_terms: D015314:Dialysis Solutions / Q000378:metabolism*; D004334:Drug Administration Schedule; D006801:Humans; D011188:Potassium / Q000097:blood* / Q000378:metabolism; D006435:Renal Dialysis / Q000379:methods*
chemical_list: D015314:Dialysis Solutions; D011188:Potassium
keywords: Clearance; dialysate; hemodialysis; kinetic model; mobilization; potassium